Alzheimer’s disease has been the most expensive disease in the U.S. since 2013. It cost American society approximately $260 billion in 2017, a sum that will rise to more than $1 trillion by 2050 unless methods to prevent Alzheimer’s disease or significantly slow its progression can be developed soon. To that end, the Bloom lab recently obtained evidence that memantine (Namenda®), an FDA-approved drug for modest and temporary symptom relief in advanced AD patients, may also be able to prevent Alzheimer’s disease. Bloom will discuss how that discovery might lead to a clinical trial to test if daily memantine treatment beginning years before Alzheimer’s disease symptoms develop can prevent or delay symptom onset.